

1 Lower Cancer Incidence Three Years After COVID-19 Infection in a Large Veteran Population

2

3 Jerry Bradley, MD¹, Fei Tang PhD², Natasha Resendes MD^{1,2}, Dominique Tosi MD^{1,2}, Iriana
4 Hammel MD^{1,2*}

5

6

7 ¹ Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA

8 ² Miami Veterans Administration (VA) Healthcare System Geriatric Research, Education, and
9 Clinical Center (GRECC), Miami, Florida, USA

10

11

12

13

14 *Corresponding author

15 Email: iriana.hammel@va.gov

16

17

18

19 Abstract

20 **Background:** The role of COVID-19 infection in cancer incidence risk is not known. COVID-19
21 infection could lead to increased cancer risk, as seen with other viruses, or it could lead to
22 decreased risk due to the activation of the immune response during acute infection. This study
23 aimed to determine the association between cancer incidence in US Veterans after COVID-19
24 infection.

25 **Methods:** We conducted a retrospective cohort study of US Veterans comparing those who
26 tested positive for COVID-19 during the first wave of COVID-19 between March 15, 2020, and
27 Nov 30, 2020, to those who tested negative. We used data from the COVID-19 Shared Data
28 Resource and used Cox proportional hazard regression models to determine the hazard ratio of a
29 new cancer diagnosis within a three-year follow-up period for the COVID-19 positive patients
30 compared to those who were negative. Covariates included age, race, ethnicity, sex, BMI,
31 smoking, being an active patient in the VHA system in the past 12 months of the COVID-19 test,
32 and other factors.

33 **Results:** 516156 patients were included in this study, with 88590 (17.2%) COVID-19 positive,
34 427566 (82.8%) COVID-19 negative. The ages of the COVID-19 positive and negative patients
35 were 57.8 ± 16.4 and 59.4 ± 15.8 , respectively. For those who survived for at least 30 days after
36 COVID-19 testing, COVID-19 infection was associated with a 32% reduction in the hazard of
37 cancer. The reduction of the hazard was similar across sexes and races, except in Asians. Above
38 45 years of age, the hazard of cancer incidence further decreases with advancing age.

39 **Conclusions:** Patients who were diagnosed with COVID-19 in the first wave of the pandemic
40 had a decreased risk of cancer incidence in a 3-year follow-up across gender and race. Further
41 multicenter prospective cohort studies are needed to evaluate the mechanism of this interaction.

42 Introduction

43 The COVID-19 pandemic has introduced a new viral factor with relatively unknown
44 effects on cancer development. Approximately 10% of cancers worldwide are virus-induced,
45 with Epstein-Barr virus (EBV), Hepatitis C virus (HCV), and human papillomavirus (HPV)
46 being examples of known viral oncogenic drivers (1). The mechanism by which viruses lead to
47 cancer development might be driven by the dysregulation of signaling pathways and alterations
48 in host DNA and RNA processes (2-4). It is unknown if, during the acute infection state of
49 COVID-19, dysregulation in immune signaling (5, 6), DNA damage with activation of pro-
50 inflammatory processes (7), or other mechanisms might increase the risk of cancer development.

51 Early in the pandemic, researchers were aware that COVID-19 induced morphological
52 and inflammatory changes in peripheral blood monocytes (8). However, the significance of these
53 changes has been debated. A recent analysis by Dr. Bharat et al. found that COVID-19 could
54 induce non-classical monocytes to act with anticancer properties (9). Specifically, they found
55 that COVID-19 single-stranded RNA (ssRNA), unlike influenza ssRNA, could increase the
56 population of this monocyte line. (9). The implication of these changes as a function of
57 monocyte exposure to COVID-19 ssRNA raises the question of whether contracting COVID-19
58 may affect cancer development in the short term.

59 Our team set out to compare the incidence of cancer in patients with COVID-19 to those
60 without. We hypothesized that patients would have a reduced risk of cancer across the board in
61 patients who were exposed to COVID-19 as compared to non-exposed patients.

62 Methods

63 Study Design, Data Sources, and Study Population

64 We conducted a retrospective cohort study to assess the association between COVID-19
65 infection and new cancer diagnoses in Veterans who were free of cancer at baseline. We
66 included Veterans who tested positive for the first time for SARS-CoV-2 (polymerase chain
67 reaction or antigen test) in VA medical centers or clinics between March 15, 2020, and
68 November 30, 2020 (Alpha/Beta waves). The control group included Veterans who had a
69 negative test result in this time frame and did not report positive test results in the next three
70 years. We excluded patients who had any cancer diagnosis at baseline and those who died within
71 30 days after SARS-CoV-2 infection. We used nationwide data from the VHA medical centers
72 from the VA COVID-19 Shared Data Resource. The Miami Veterans Affairs Healthcare System
73 Institutional Review Board approved this study. The IRB granted a waiver for informed consent.
74 The data was fully anonymized according to VHA standards prior to analysis. The data was
75 accessed on 01/10/2024 to 17/12/2024.

76 Study Outcome

77 The primary outcome was any cancer diagnosis after COVID-19 testing (positive or negative) as
78 documented by ICD-10 codes.

79 Covariates

80 Age, race, ethnicity, sex, BMI, smoking, kidney disease, COPD, diabetes, hypertension,
81 hyperlipidemia, obesity, chronic lung disease, PTSD, alcohol dependence, drug dependence,
82 being an active patient in the past 12 months, exposure to toxic substances, other viral infections

83 such as a history of exposure to Hepatitis B, Hepatitis C, cytomegalovirus, mononucleosis, HIV
84 among others, and immunodeficiency conditions secondary to prior history transplant or
85 conditions related to immune response.

86 Statistical Analysis

87 Continuous variables are presented as mean \pm standard deviation, median with interquartile
88 range, and categorical variables as frequencies and percentages. When information on race,
89 ethnicity and smoking status was not available, we reported the data as “Unknown.” The Cox
90 proportional hazard model was used to evaluate the association between COVID-19 and cancer
91 diagnosis, adjusting for the covariates listed above. The proportional hazards assumption was
92 assessed and verified by testing the correlation between the Schoenfeld residuals and survival
93 time. Time-to-event analyses began 30 days after the date of infection, and patients were
94 censored on the date of death or at the end of the years of follow-up. The association was also
95 assessed in patients of different age groups, sexes, and races. Statistical analysis was performed
96 using R (R project for statistical computing, version 4.0.5).

97 Results

98 Baseline Characteristics

99 A total of 516,156 Veterans with SARS-CoV-2 testing in 2020 were included in this
100 retrospective cohort study, with 346,084 (67.1%) white, 112,476 (21.8%) black, 44,392 (8.6%)
101 Hispanic, 45,5388 (88.2%) males. A total of 88,590 (17.2%) patients tested positive for SARS-
102 CoV-2. The baseline characteristics of the study cohort are summarized in Table 1. The mean
103 age of the entire cohort was 59.1 ± 16.0 years (median 62 years), with COVID-19 positive and

104 negative patients having similar ages (57.8±16.4 vs 59.4±15.8). The COVID-19 positive and
 105 negative patients were similar in terms of other baseline characteristics, as well.

	Total n = 516156 (100%)	COVID-19 Negative n = 427566 (82.8%)	COVID-19 Positive n = 88590 (17.2%)
Age, mean (years) ±SD (median; IQR)	59.1±16.0 (62; 48-71)	59.4±15.8 (62; 49-71)	57.8±16.4 (59; 45-71)
Age Groups, n (%)			
19-64	220523 (42.7%)	185873 (43.5%)	34650 (39.1%)
≥65	295633 (57.3%)	241693 (56.5%)	53940 (60.9%)
Male sex, n (%)	455388 (88.2%)	376833 (88.1%)	78555 (88.7%)
Race, n (%)			
White	346084 (67.1%)	288910 (67.6%)	57174 (64.5%)
Black	112476 (21.8%)	91545 (21.4%)	20931 (23.6%)
Asian	6256 (1.2%)	5397 (1.3%)	859 (1.0%)
American Indian or Alaska Natives	4378 (0.8%)	3496 (0.8%)	882 (1.0%)
Native Hawaiian or Other Pacific Islander	4783 (0.9%)	3919 (0.9%)	864 (1.0%)
Unknown	42179 (8.2%)	34299 (8.0%)	7880 (8.9%)
Ethnicity, n (%)			
Hispanic	44392 (8.6%)	34365 (8.0%)	10027 (11.3%)
Not Hispanic	457677 (85.7%)	381616 (89.3%)	76061 (85.9%)
Unknown	14087 (2.7%)	11585 (2.7%)	2502 (2.8%)
Smoking, n (%)			
Current	109559 (21.2%)	98650 (23.1%)	10909 (12.3%)
Former Smoker	192443 (37.3%)	157933 (36.9%)	34510 (39.0%)
Never	169205 (32.8%)	134629 (31.5%)	34576 (39.0%)
Unknown	44949 (8.7%)	36354 (8.5%)	8595 (9.7%)
Comorbidity, n (%)			
Kidney Disease	101248 (19.6%)	84599 (19.8%)	16649 (18.8%)
COPD	84592 (16.4%)	73056 (17.1%)	11536 (13.0%)
Diabetes	153007 (29.6%)	125141 (29.3%)	27866 (31.5%)
Hypertension	296271 (57.4%)	246537 (54.5%)	49734 (54.8%)
Chronic Lung Disease	160078 (31.0%)	135996 (31.8%)	24082 (27.2%)
Overweight	35361 (6.9%)	27676 (8.7%)	7685 (6.5%)
Toxic exposure	3911 (0.8%)	3321 (0.8%)	590 (0.7%)
Alcohol Dependency	123841 (24.0)	104676 (24.5%)	19165 (21.6%)

Drug Dependency	35969 (7.0%)	32203 (7.5%)	3766 (4.3%)
Immunodeficiency	14572 (2.8%)	12442 (2.9%)	2130 (2.4%)
Mortality	88414 (17.1%)	72621 (16.4%)	15793 (16.9%)

106 **Table 1.** Baseline Characteristics.

107 **Association of COVID-19 Infection and Decreased Cancer Risk**

108 Having a positive COVID-19 infection was associated with a 25% decrease in the hazard of
 109 having a cancer diagnosis in the three years follow-up (HR=0.75, 95% CI: 0.74-0.77),
 110 controlling for age, race, ethnicity, sex, BMI, smoking, kidney disease, COPD, diabetes,
 111 hypertension, hyperlipidemia, obesity, chronic lung disease, PTSD, alcohol dependence, drug
 112 dependence, being an active patient in the past 12 months, exposure to toxic substances, other
 113 viral infections, and immunodeficiency.

114

	Number of events (%)	aHR (95% CI)
18-24 (n=3549)	17 (0.5%)	1.16 (0.37-3.63)
24-34 (n=44690)	383 (0.9%)	0.85 (0.65-1.12)
35-44 (n=61155)	1130 (1.8%)	0.93 (0.80-1.09)
45-54 (n=73400)	3334 (4.5%)	0.87 (0.79-0.95)
55-64 (n=112828)	11055 (9.8%)	0.84 (0.80-0.89)
65-74 (n=146407)	25956 (17.7%)	0.76 (0.73-0.79)
75-84 (n=53915)	11549 (21.4%)	0.74 (0.70-0.78)
85-99 (n=20201)	4155 (20.6%)	0.64 (0.58-0.70)

115 **Table 2.** aHR for New Cancer Diagnosis within three years for Patients with Positive COVID-19
 116 Testing Compared to Patients of Negative Testing by Age

117

118 Association of COVID-19 Infection and Decreased Cancer Risk
119 by Age Groups, Gender, and Race.

120 We assessed the association between positive COVID-19 infection and the risk of having a
121 cancer diagnosis within three years in different age groups. We found that the older groups
122 showed a greater reduction in the hazard of new cancer diagnosis. For the age group of 85-99,
123 having a positive COVID-19 infection was associated with a 36% decrease in the hazard of
124 having a cancer diagnosis in the three years follow-up (aHR: 0.64, 95% CI: 0.58-0.70), for age
125 group of 75-84, the reduction was 26% (aHR: 0.74, 95% CI: 0.70-0.78); and for the age group of
126 55-64, the reduction was 16% (aHR: 0.84, 95% CI: 0.80-0.89) (Table 2). Regarding sex, the
127 reduction in new cancer diagnosis was slightly higher in men (aHR: 0.74, 95% CI: 0.70-0.78)
128 than in women (aHR: 0.85, 95% CI: 0.76-0.94) (Table 3). Regarding race and ethnicity, the
129 reduction in new cancer diagnoses was similar between white, black, Asian, and Hispanic
130 populations (Table 4).

131

	aHR (95%CI)
Man	0.74 (0.73-0.76)
Women	0.85 (0.76-0.94)

132 **Table 3.** aHR for New Cancer Diagnosis within three years for patients with positive COVID-19
133 testing compared to patients with negative testing by sex.

134

135

	aHR (95% CI)
Black	0.79 (0.74-0.84)
White	0.74 (0.72-0.76)
Hispanic	0.76 (0.69-0.86)
Asian	0.76 (0.49-1.17)

136 **Table 4.** aHR for New Cancer Diagnosis within three years for Patients with Positive COVID-19
137 Testing Compared to Patients of Negative Testing by Race and Ethnicity.

138 Discussion

139 COVID-19 Exposure and Cancer Risk

140 Our findings show that beyond the age of 45, exposure to COVID-19 is associated with a
141 reduction in cancer incidence across all major cancer types. It is plausible that the immunologic
142 changes that occur during acute COVID-19 infection (10, 11) might lead to the activation of
143 monocytes with anticancer properties, as has been reported by other investigators (9), or another
144 process may lead to heightened immunity that has not been identified. The inflammatory
145 response to COVID-19 may have a short-term protective benefit that wanes over time.
146 Therefore, it is uncertain how long this risk reduction might be observed in the long-term beyond
147 the 3-year period of this study. Further research and longer follow-up periods are required to
148 fully understand the mechanisms responsible for the reduction in cancer incidence.

149 Pandemic Healthcare Disruptions

150 COVID-19 has introduced several new healthcare disruptions in cancer surveillance.
151 Cancer trends during the pandemic showed an initial reduction, followed by a general return to
152 the pre-pandemic levels (12, 13). These changes were expected, given the drastic reduction in
153 preventive services in the US (14). An analysis of trends in US cancer rates revealed the highest
154 variability in breast, cervical, prostate, and colorectal cancers, likely driven by a reduction in
155 surveillance screening (15). For this study, patients were analyzed for three years after the initial
156 index infection. This timeframe was extended to include the post-pandemic return to standard
157 screening; hence, the reduction we saw in our results is likely not a reflection of reduced
158 screening or missed diagnosis.

159 Age and Racial Differences

160 Racial and sex disparities are known to exist after COVID-19 infection, with men being
161 more likely to have adverse outcomes after infection (16). These racial and gender disparities
162 have improved over time (17) but remain an active area of investigation. Our findings showed
163 that the overall rate of cancer reduction was the same regardless of race or sex, except for
164 Asians, who comprised a small percentage of VA users. These findings were unexpected given
165 the known racial and ethnic disparities in cancer incidence (18). The relative uniformity of this
166 reduction across both sexes and races suggests the potential of a biological process independent
167 of these factors.

168 Regarding age, the incidence of cancer appeared to decrease with each decade of life in
169 the COVID-19 group compared to that in the non-exposed group. This is surprising, given that
170 cancer diagnoses typically increase with age. Several factors may contribute to this finding.

171 Older patients have a higher rate of death than younger patients with COVID-19 (19). Our study
172 examined patients during the initial alpha and delta waves. During the pandemic, mortality rates
173 reached their highest point in the delta-wave cohort (20). We attempted to mitigate the risk of
174 survival bias by censoring and multivariate analyses for potential confounders. Our study
175 showed that mortality rates were similar between groups after the 30-day period. However,
176 several factors remain that cannot be adjusted through statistical processes. Given the reduction
177 in cancer rates across the board in the infected cohort, patients in this group who survived the
178 initial infection may have been at a lower risk for cancer due to environmental or genetic
179 reasons. Similarly, the increased mortality in this group could have conferred a survival
180 advantage regarding cancer risk. Therefore, care must be taken when attempting to link viral
181 exposure to reduced cancer outcomes, as these findings do not support causation.

182 Strengths and Limitations

183 Given the retrospective and observational nature of this study, the findings should be
184 interpreted with caution. One of the strengths of this study is that it comprises a large nationwide
185 database in which multiple risk factors and outcomes can be analyzed. An initial limitation of the
186 study is that this is only a 3-year cohort analysis of cancer incidence in a Veteran population that
187 is mostly comprised of male patients. These findings might change as five and ten-year data
188 become available and may be different in non-Veteran populations. Additionally, we attempted
189 to count for re-infection data; however, we were unable to capture all cases due to the increased
190 availability of COVID-19 testing outside of the VA (at-home testing, state, and county testing
191 sites, among others) during subsequent re-infections and potentially milder disease or other
192 medical and socioeconomic reasons for which veterans did not seek medical attention. It is

193 unknown how reinfection alters the risk of cancer development in these patients, and the extent
194 to which it might induce other physiological changes.

195 Conclusion

196 Despite the limitations of our retrospective observational study, cancer incidence appears
197 to be lower in patients diagnosed with COVID-19 across all major cancers and independent of
198 race or sex. Further research is required to determine the precise causes and mechanisms
199 underlying these findings.

200 Acknowledgments

201 We would like to acknowledge the support of the Miami VAMC, Geriatric Research
202 Education and Clinical Center, and the US Veterans who served as our study population. This
203 study was supported using resources and facilities of VINCI, VA HSR RES 13-457

204

205

206

207

208

209

210

211

212
213
214
215
216

217 References

- 218 1. Schiller JT, Lowy DR. An Introduction to Virus Infections and Human Cancer. *Recent*
219 *Results Cancer Res.* 2021;217:1-11.
- 220 2. Kellogg C, Kouznetsova VL, Tsigelny IF. Implications of viral infection in cancer
221 development. *Biochim Biophys Acta Rev Cancer.* 2021;1876(2):188622.
- 222 3. Morales-Sánchez A, Fuentes-Pananá EM. Human viruses and cancer. *Viruses.*
223 2014;6(10):4047-79.
- 224 4. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of
225 human tumour virology. *Nat Rev Cancer.* 2010;10(12):878-89.
- 226 5. Suryawanshi RK, Koganti R, Agelidis A, Patil CD, Shukla D. Dysregulation of Cell
227 Signaling by SARS-CoV-2. *Trends Microbiol.* 2021;29(3):224-37.
- 228 6. Turnbull IR, Fuchs A, Remy KE, Kelly MP, Frazier EP, Ghosh S, et al. Dysregulation of
229 the leukocyte signaling landscape during acute COVID-19. *PLoS One.* 2022;17(4):e0264979.
- 230 7. Gioia U, Tavella S, Martínez-Orellana P, Cicio G, Colliva A, Cecon M, et al. SARS-
231 CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1
232 recruitment, and cellular senescence. *Nature Cell Biology.* 2023;25(4):550-64.
- 233 8. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et al. Frontline Science: COVID-19
234 infection induces readily detectable morphologic and inflammation-related phenotypic changes
235 in peripheral blood monocytes. *J Leukoc Biol.* 2021;109(1):13-22.
- 236 9. Liu X, Ren Z, Tan C, Núñez-Santana FL, Kelly ME, Yan Y, et al. Inducible CCR2+
237 nonclassical monocytes mediate the regression of cancer metastasis. *J Clin Invest.* 2024;134(22).
- 238 10. Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an Acute Inflammatory
239 Disease. *J Immunol.* 2020;205(1):12-9.
- 240 11. Wong RSY. Inflammation in COVID-19: from pathogenesis to treatment. *Int J Clin Exp*
241 *Pathol.* 2021;14(7):831-44.
- 242 12. Drescher CW, Bograd AJ, Chang SC, Weerasinghe RK, Vita A, Bell RB. Cancer case
243 trends following the onset of the COVID-19 pandemic: A community-based observational study
244 with extended follow-up. *Cancer.* 2022;128(7):1475-82.
- 245 13. Decker KM, Feely A, Bucher O, Czaykowski P, Hebbard P, Kim JO, et al. New Cancer
246 Diagnoses Before and During the COVID-19 Pandemic. *JAMA Netw Open.*
247 2023;6(9):e2332363.
- 248 14. Huggins A, Husaini M, Wang F, Waken RJ, Epstein AM, Orav EJ, et al. Care Disruption
249 During COVID-19: a National Survey of Hospital Leaders. *Journal of general internal medicine.*
250 2023;38(5):1232-8.

- 251 15. Shanmugam R, Fulton L, Kruse CS, Beauvais B, Betancourt J, Pacheco G, et al. The
252 effect of COVID-19 on cancer incidences in the U.S. *Heliyon*. 2024;10(7):e28804.
- 253 16. Pal S, Gangu K, Garg I, Shuja H, Bobba A, Chourasia P, et al. Gender and Race-Based
254 Health Disparities in COVID-19 Outcomes among Hospitalized Patients in the United States: A
255 Retrospective Analysis of a National Sample. *Vaccines (Basel)*. 2022;10(12).
- 256 17. Nguemeni Tiako MJ, Browne A. How race, sex and age interact in association with
257 COVID-19 outcomes over time: An analysis of Michigan data. *PLoS One*. 2023;18(8):e0288383.
- 258 18. Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa
259 MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. *Br J Cancer*.
260 2021;124(2):315-32.
- 261 19. Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V,
262 Fácila L, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis
263 With 611,583 Subjects. *J Am Med Dir Assoc*. 2020;21(7):915-8.
- 264 20. Lundberg DJ, Wrigley-Field E, Cho A, Raquib R, Nsoesie EO, Paglino E, et al. COVID-
265 19 Mortality by Race and Ethnicity in US Metropolitan and Nonmetropolitan Areas, March 2020
266 to February 2022. *JAMA Netw Open*. 2023;6(5):e2311098.

267